我国在研创新药占全球30%左右，恒生创新药ETF（159316）、医药ETF（512010）等助力布局产业发展机遇

Core Insights - The Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 0.6%, while the CSI Innovative Drug Industry Index rose by 0.7%, the CSI Biotechnology Theme Index by 0.8%, the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index by 1.1%, and the CSI 300 Medical and Health Index by 1.8% this week [1][3] - The Hang Seng Innovative Drug ETF (159316) saw a net inflow of 330 million yuan this week, bringing its total size to over 1.57 billion yuan, a record high [1] - The National Medical Products Administration's deputy director emphasized the commitment to ensuring drug safety and supporting high-quality development of the pharmaceutical industry during the "14th Five-Year Plan" period, with China's pharmaceutical industry ranking second globally and accounting for about 30% of the world's innovative drugs under research [1] Index Performance - Weekly performance of various indices: - Hang Seng Hong Kong Stock Connect Innovative Drug Index: +0.6% - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: +1.1% - CSI Innovative Drug Industry Index: +0.7% - CSI Biotechnology Theme Index: +0.8% - CSI 300 Medical and Health Index: +1.8% [3] - Year-to-date performance shows significant growth, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index up by 112.0% and the CSI 300 Medical and Health Index up by 16.8% [6] Index Composition - The CSI Hong Kong Stock Connect Medical and Health Comprehensive Index consists of 50 stocks from the medical device, biopharmaceutical, chemical drug, and other healthcare sectors [4] - The CSI Innovative Drug Industry Index focuses on A-share innovative drug leaders, comprising no more than 50 stocks involved in innovative drug research and development [4] - The CSI Biotechnology Theme Index includes no more than 50 stocks related to gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [4]